trial

Varenicline and Smoking Cessation in Schizophrenia

NCTId NCT01111149
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 24 (actual)
Sponsored by University of Minnesota
Primary completion 2012-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Double
Start
2009-12
Primary completion
2012-08
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Sugar PillVareniclineBupropion HCl

Sponsors

University of MinnesotaLead Sponsor
National Institutes of Health (NIH)Collaborator
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
S. Hossein Fatemi, M.D., Ph.D.Principal Investigator

Sites

1 total
Minneapolis, United States

Linked catalysts

1
Varenicline and Smoking Cessation in Schizophrenia — primary completion2012-08

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE2
Primary Completion Date
2012-08
Status
COMPLETED
relationships
The graph out of here
drug
Sugar Pill
drug
Varenicline
drug
Bupropion HCl
drug
lead_sponsor
University of Minnesota
company
collaborator
National Institutes of Health (NIH)
company
National Institute on Drug Abuse (NIDA)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Smoking Cessation
indication
investigator
S. Hossein Fatemi, M.D., Ph.D.
person